A Phase 2 Study of Sotorasib to Treat Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer

In the U.S.

Full Title

A Phase 2 Study of First-line Sotorasib for Patients with Advanced KRAS G12C-mutant Non-Small Cell Lung Cancer

Purpose

The purpose of this study is to see how well sotorasib works in people with advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) with a mutation (change) in the KRAS G12C gene. This mutation can cause cancer cells to grow. In addition, the people in this study have not received treatment for their cancer since it became advanced.

Sotorasib is a standard treatment for advanced NSCLC with a KRAS G12C mutation. However, doctors normally give this drug to people who have already received another medication for advanced NSCLC. Researchers are doing this study to assess sotorasib as initial therapy for advanced NSCLC with a KRAS G12C mutation.

Sotorasib targets and blocks the mutated KRAS G12C protein. By blocking this protein, sotorasib may slow or stop the growth of your cancer. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

Have NSCLC with a KRAS G12C mutation.
Have not received anti-cancer medication for advanced NSCLC.
Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
Be age 18 or older.